Jääskeläinen A, Roininen N, Karihtala P and Jukkola A (2020) High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. Front. Oncol. 10:1470. doi: 10.3389/fonc.2020.01470
High parity predicts poor outcomes in patients with luminal B-like (HER2 negative) early breast cancer : a prospective Finnish single-center study
|Author:||Jääskeläinen, Anniina1; Roininen, Nelli1; Karihtala, Peeter1,2;|
1Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre, University of Helsinki, Helsinki, Finland
3Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
4Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
5Tampere Cancer Center, Tampere, Finland
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020120198873
|Publish Date:|| 2020-12-01
While breast cancer prognoses are generally good, different molecular subtypes are known to have varying outcomes. Previous studies using breast cancer registries have suggested that high parity may be an adverse prognostic factor in luminal breast cancer, but breast cancer subtype definitions have varied and there have been few prospective studies. We therefore collected prospective data from patients diagnosed with early breast cancer at a single institution and followed them for a median of 8.5 years. All patients (N = 594) were treated according to Finnish national guidelines using modern treatment modalities in a Finnish university hospital. Clinicopathological surrogates of the intrinsic breast cancer subtypes were updated to match European Society for Medical Oncology 2015 Early Breast Cancer Clinical Practice Guidelines. The overall 10-year breast cancer–specific survival (BCSS) was 91.4%, with the longest 10-year BCSS observed in luminal A-like cancers (97.9%) and the worst in luminal B-like (HER2 positive) cancers (80.6%). Parity of ≥ 5 deliveries was also associated with poor BCSS (univariate P = 0.0020). However, when the subtypes were assessed separately in a multivariate analysis that included tumor size and nodal status, high parity remained significant only in luminal B-like (HER2 negative) cancers (HR = 2.63; 95% confidence interval = 1.04–6.62; P = 0.040). Our results suggest excellent overall 10-year BCSS but indicate that high parity is an adverse prognostic factor in luminal B-like (HER2 negative) breast cancers.
Frontiers in oncology
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was supported by the Cancer Foundation of Finland, the Cancer Society of Northern Finland, the Pink Ribbon Association, the University of Oulu Scholarship Foundation, and the Finnish Medical Foundation.
© 2020 Jääskeläinen, Roininen, Karihtala and Jukkola. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.